HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Putative Gonadotropin-Releasing Hormone Agonist Therapy and Dementia: An Application of Medicare Hospitalization Claims Data.

AbstractBACKGROUND:
Estrogen and hormone replacement therapies to reduce Alzheimer's disease (AD) have yielded conflicting results. However, this study proposes that the well-characterized increase in serum gonadotropins following menopause or andropause are accountable for the increased risk of developing AD among the elderly population.
OBJECTIVE:
To determine the role of gonadotropins in the development of AD and investigate gonadotropin-releasing hormone (GnRH) agonist therapy as a potential preventative and/or disease-modifying approach to AD management.
METHODS:
Male Medicare beneficiaries aged 67 to 75 and hospitalized with prostate cancer (n = 115,789) were compared to three control groups: men of the same demographics undergoing a cholecystectomy (n = 97,267), herniorrhaphy (n = 68,778), or transurethral prostatectomy (n = 267,691). A proportion of the patients hospitalized with prostate cancer were assumed to have low concentrations of serum gonadotropins and sex steroids as a result of GnRH agonist therapy, while those in the control groups were assumed to have elevated gonadotropin but lowered sex steroid levels that are associated with andropause in this age group.
RESULTS:
The rates of development of select diagnoses of dementia, including AD, over a twelve-year follow-up period following surgery. When compared to control patients, men hospitalized with prostate cancer have a protection against dementia after twelve years of follow-up, with relative risks ranging from 0.48 to 0.83.
CONCLUSION:
Patients with prostate cancer are treated with the GnRH analogue leuprolide acetate, our data suggest that leuprolide acetate may be therapeutic for AD via its downregulation of serum gonadotropins.
AuthorsMark A Smith, Richard L Bowen, Richard Q Nguyen, George Perry, Craig S Atwood, Alfred A Rimm
JournalJournal of Alzheimer's disease : JAD (J Alzheimers Dis) Vol. 63 Issue 4 Pg. 1269-1277 ( 2018) ISSN: 1875-8908 [Electronic] Netherlands
PMID29782310 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Hormones
  • Gonadotropin-Releasing Hormone
Topics
  • Aged
  • Dementia (drug therapy, epidemiology)
  • Gonadotropin-Releasing Hormone (agonists, metabolism)
  • Hormones (therapeutic use)
  • Hospitalization
  • Humans
  • Longitudinal Studies
  • Male
  • Medicare
  • Prostatic Neoplasms (epidemiology, surgery)
  • Retrospective Studies
  • United States

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: